TRPV1 Gates Tissue Access and Sustains Pathogenicity in Autoimmune Encephalitis

• Published in: Molecular Medicine
• Main Authors: Geoffrey Paltser, Xue Jun Liu, Jason Yantha, Shawn Winer, Hubert Tsui, Ping Wu, Yuko Maezawa, Lindsay S. Cahill, Christine L. Laliberté, Sreeram V. Ramagopalan, Gabriele C. DeLuca, A. Dessa Sadovnick, Igor Astsaturov, George C. Ebers, R. Mark Henkelman, Michael W. Salter, H.-Michael Dosch
• Format: Article
• Language: English
• Published: BMC 2013-05-01
• Subjects: Transient Receptor Potential Vanilloid (TRPV1); Experimental Autoimmune Encephalomyelitis; TRPV1 Activation; Blood-spinal Cord Barrier (BSCB); TRPV1 Expression
• Online Access: https://doi.org/10.2119/molmed.2012.00329
• ISSN: 1076-1551; 1528-3658

Abstract Multiple sclerosis (MS) is a chronic progressive, demyelinating condition whose therapeutic needs are unmet, and whose pathoetiology is elusive. We report that transient receptor potential vanilloid-1 (TRPV1) expressed in a major sensory neuron subset, controls severity and progression of experimental autoimmune encephalomyelitis (EAE) in mice and likely in primary progressive MS. TRPV1−/− B6 congenics are protected from EAE. Increased survival reflects reduced central nervous systems (CNS) infiltration, despite indistinguishable T cell autoreactivity and pathogenicity in the periphery of TRPV1-sufficient and -deficient mice. The TRPV1+ neurovascular complex defining the blood-CNS barriers promoted invasion of pathogenic lymphocytes without the contribution of TRPV1-dependent neuropeptides such as substance P In MS patients, we found a selective risk-association of the missense rs877610 TRPV1 single nucleotide polymorphism (SNP) in primary progressive disease. Our findings indicate that TRPV1 is a critical disease modifier in EAE, and we identify a predictor of severe disease course and a novel target for MS therapy.